Myovant Sciences Operating Income 2017-2022 | MYOV

Myovant Sciences operating income from 2017 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Myovant Sciences Annual Operating Income
(Millions of US $)
2022 $-187
2021 $-261
2020 $-275
2019 $-265
2018 $-141
2017 $-56
2016 $-2
Myovant Sciences Quarterly Operating Income
(Millions of US $)
2022-03-31 $-52
2021-12-31 $-60
2021-09-30 $-18
2021-06-30 $-57
2021-03-31 $-77
2020-12-31 $-78
2020-09-30 $-72
2020-06-30 $-34
2020-03-31 $-64
2019-12-31 $-78
2019-09-30 $-67
2019-06-30 $-65
2019-03-31 $-72
2018-12-31 $-69
2018-09-30 $-64
2018-06-30 $-60
2018-03-31 $-47
2017-12-31 $-42
2017-09-30 $-30
2017-06-30 $-22
2017-03-31 $-23
2016-12-31 $-9
2016-09-30 $-7
2016-06-30 $-17
2016-03-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.313B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00